BCL2 and cancer: Therefore, blocking the antiapoptotic and poor prognostic marker BCL2 and inducing the exogenous expression of the pro-apoptotic and favorable prognostic marker BAX in cancer tissues, could be considered in the development of antioncogenic therapies strategies.